KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2016 - 2026)

Pacific Biosciences Of California has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $784.1 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 37.79% year-over-year to $784.1 million; the TTM value through Dec 2025 reached $3.3 billion, down 44.42%, while the annual FY2025 figure was $784.1 million, 37.79% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $784.1 million at Pacific Biosciences Of California, down from $803.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $2.0 billion in Q4 2021 and troughed at $784.1 million in Q4 2025.
  • A 5-year average of $1.5 billion and a median of $1.7 billion in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 483.1% in 2021 and later tumbled 48.45% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $2.0 billion in 2021, then decreased by 11.95% to $1.8 billion in 2022, then fell by 1.19% to $1.7 billion in 2023, then decreased by 27.81% to $1.3 billion in 2024, then tumbled by 37.79% to $784.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for PACB at $784.1 million in Q4 2025, $803.2 million in Q3 2025, and $825.5 million in Q2 2025.